PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.
PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.
A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).
|PGx Test||Variants Assayed||Related Drugs?|
|Alternate Symbols: ||HK4|
|PharmGKB Accession Id:||PA28610|
|Cytogenetic Location:||chr7 : p15.3 - p15.1|
|GP mRNA Boundary†:||chr7 : 44183870 - 44229022|
|GP Gene Boundary†:||chr7 : 44180870 - 44239022|
PharmGKB Curated Pathways
Pathways created internally by PharmGKB based primarily on literature evidence.
Anti-diabetic Drug Potassium Channel Inhibitors Pathway, Pharmacodynamics
Representation of anti-diabetic drugs repaglinide, nateglinide and sulfonylurea effects on insulin secretion in pancreatic cells.
Links to non-PharmGKB pathways.
- FOXA2 and FOXA3 transcription factor networks - (Pathway Interaction Database NCI-Nature Curated)
- HIF-1-alpha transcription factor network - (Pathway Interaction Database NCI-Nature Curated)
- Negative Regulation of Glucokinase by Glucokinase Regulatory Protein - (Reactome via Pathway Interaction Database)
Publications related to GCK: 6
The following icons indicate that data of a certain type is available:
- DG Dosing Guideline information is available
- DL Drug Label information is available
- CA High-level Clinical Annotation is available
- VA Variant Annotation is available
- VIP VIP information is available
- PW Pathway is available
[ close ]
||Large-Scale Gene-Centric Meta-analysis across 32 Studies Identifies Multiple Lipid Loci. American journal of human genetics. 2012. Asselbergs Folkert W, et al.|
||A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nature genetics. 2012. Manning Alisa K, et al.|
||Effects of genetic variants previously associated with fasting glucose and insulin in the diabetes prevention program. PloS one. 2012. Florez Jose C, et al.|
||New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nature genetics. 2010. Dupuis Josée, et al.|
||Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug discovery today. 2009. Pal Manojit.|
||Exendin-4 differentiation of a human pancreatic duct cell line into endocrine cells: involvement of PDX-1 and HNF3beta transcription factors. Journal of cellular physiology. 2002. Zhou Jie, et al.|